MyDosage · Personal evidence dossier

Skin & hair

Topical and systemic candidates for skin quality and pigmentation.

DSR-SKIN-20260820

Issued August 20, 2026

Editorial · independent

01Top candidate

Melanotan I

α-MSH analogue · t½ ~30 min (free); implant releases over months

Linear α-MSH analogue (afamelanotide), approved as Scenesse for erythropoietic protoporphyria.

Evidence Intelligence Score™

6.3/ 10Moderate

Strongest

Effects on the indexed outcomes are supported by randomized human data, with 1 citation on file.

Weakest

Effect sizes outside trial populations and durations beyond the studied window remain less characterized.

Unknowns

Interactions outside listed contraindications, long-term safety, and effect heterogeneity across age and sex are not fully resolved.

Outlook

Outlook: maturing. Expect the consensus to harden as multi-site replications publish.

02Ranked candidates

03Safety register

Melanotan I
Pregnancy · Active melanoma
GHK-Cu
Wilson's disease · Copper sensitivity
Melanotan II
Pregnancy · Personal/family melanoma · History of moles/dysplastic nevi